Comparative Pharmacology
Head-to-head clinical analysis: DYNACIN versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIN versus TETREX.
DYNACIN vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
100 mg orally twice daily or 200 mg orally once daily.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days.
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%).
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic